AMP-ACTIVATED PROTEIN KINASE AND P38 MAP KINASE ACTIVATE O-GLCNACYLATION OF NEURONAL PROTEINS DURING GLUCOSE DEPRIVATION

Win D. Cheung and Gerald W. Hart

From the Department of Biological Chemistry
The Johns Hopkins University School of Medicine, Baltimore, Maryland, 21205-2185

Running title: AMPK and p38 regulate OGT

We have previously demonstrated that a wide array of stress signals induces O-GlcNAc transferase (OGT) expression and increases O-GlcNAcylation of many intracellular proteins, and this response is critical for cell survival. Here, we describe a mechanism by which glucose deprivation induces OGT expression and activity in Neuro-2a neuroblastoma cells. Glucose deprivation increases OGT mRNA and protein expression in an AMP-activated protein kinase-dependent manner, while OGT enzymatic activity is regulated in a p38 MAP kinase-dependent manner. OGT is not phosphorylated by p38, but rather interacts directly with p38 through its C-terminus, and this interaction increases with p38 activation during glucose deprivation. Surprisingly, OGT’s catalytic activity, as measured toward peptide substrates, is not altered by glucose deprivation. Instead, p38 regulates OGT’s activity within the cell by recruiting it to specific targets, including neurofilament H. Neurofilament H is O-GlcNAcylated during glucose deprivation in a p38-dependent manner. Interestingly, neurofilament H solubility is increased by glucose deprivation in an O-GlcNAc-dependent manner, suggesting that O-GlcNAcylation of neurofilament H regulates its disassembly from filaments. Not only do these data help to reveal how OGT is regulated by stress, but these findings also describe a possible mechanism by which defective brain glucose metabolism, as found in aging and ischemia, may directly affect axonal structure.

During periods of ischemia, cells experience a severe depletion of extracellular glucose and oxygen, resulting in the activation of numerous stress signaling pathways regulating cell survival (1-4). The brain is extraordinarily sensitive to ischemic conditions, due in part to its large demand for glucose as an energy source (5). Upon ischemia, axonal damage is known to occur, eventually resulting in impairment of brain function (6,7). While excitotoxicity and oxidative stress have been shown to contribute to axon injury during ischemia (8), the mechanisms governing the loss of axon structure itself are not completely understood.

We have shown that many stresses increase protein O-GlcNAcylation and promote cell survival by increasing Hsp70 expression via O-GlcNAc transferase (OGT) expression and activity (9). However, the mechanisms by which protein O-GlcNAcylation is regulated under these and other conditions are unclear.

The modification of proteins in the cytosol and nucleus with the monosaccharide O-linked beta-N-acetylglucosamine (O-GlcNAc) has now been described for more than 20 years (for review see (10)). Protein O-GlcNAcylation is an abundant and dynamic post-translational modification of serine and threonine residues essential for life in multicellular organisms (11,12). Many O-GlcNAcylation sites also are, or adjacent to, known phosphorylation sites, illustrating a complex relationship between O-GlcNAcylation- and phosphorylation-mediated signaling (13-18). Greater than 500 proteins have now been identified as O-GlcNAcylated, including proteins involved in regulation of the cell cycle, transcription, trafficking, and signaling (19-21).

O-linked beta-N-acetylglucosaminidase (O-GlcNAcase), which catalyzes the hydrolysis of O-GlcNAc from proteins, is a nucleocyttoplasmic neutral hexosaminidase that also has a domain with high similarity to known acetyltransferases (22,23). The O-GlcNAcase gene (MGEA5) resides at chromosome 10q24.1, a locus associated with neurodegenerative disease (24,25). OGT, which catalyzes the addition of O-GlcNAc to proteins using UDP-GlcNAc as the donor nucleotide, resides on the X chromosome at Xq13,
a locus also associated with neurological disorders (11,26). We have demonstrated previously that OGT’s activity in vitro is linearly responsive to a large range of UDP-GlcNAc concentrations (27). In fact, OGT’s ability to recognize certain peptide substrates seems to be affected by [UDP-GlcNAc] (27). UDP-GlcNAc levels have been shown to change with glucose concentrations (28,29), consistent with a role for O-GlcNAcylation in nutrient sensing and diabetes (20,30).

Approximately 2 – 5 % of the glucose that enters the cell is converted into UDP-GlcNAc de novo, via the hexosamine biosynthetic pathway (31). Intracellular UDP-GlcNAc concentrations are typically in the 100 micromolar to low millimolar range, similar to ATP (29,32). During conditions of low glucose, [ATP] and [UDP-GlcNAc] are known to decrease while [AMP] is known to increase, leading to activation of the AMP-activated protein kinase (AMPK) pathway (33). Activation of AMPK has been previously shown to regulate cell survival by phosphorylating tuberin (TSC2), leading to inhibition of mammalian target of rapamycin (mTOR) and inhibition of cell growth (for review see (34)).

Low glucose conditions also activate the p38 MAP kinase pathway (35,36). p38 is a member of the stress-activated protein kinase family (for review see (3)), and its activation during energy depletion affects neuronal survival (36). Unfortunately, the mechanisms by which p38 regulates survival in response to glucose deprivation are not clearly understood. Interestingly, a recent high-throughput protein interaction analysis suggested that OGT may interact directly with p38 (37).

We demonstrate that glucose deprivation indeed decreases UDP-GlcNAc concentrations, yet paradoxically leads to a dramatic increase in protein O-GlcNAcylation, in agreement with other reports (38). Here, we further show that this response is mediated by AMPK-dependent OGT expression and p38-dependent OGT activation, consistent with OGT’s activation by cellular stress. We also show that neurofilament H is O-GlcNAcylated during glucose deprivation, altering its function, and providing a possible explanation for the loss of axons in ischemia. These findings represent an important advance in our understanding of mechanisms regulating O-GlcNAcylation by OGT, and the findings have important implications for stress signaling relevant to neurodegeneration, aging, and cancer.

EXPERIMENTAL PROCEDURES

Cell Culture and Treatments – Neuro-2a murine neuroblastoma cells were obtained from the ATCC and maintained in DMEM (5 mM glucose; Mediatech) supplemented with 10 % (v/v) fetal bovine serum (FBS; Gemini Bio-Products) and penicillin/streptomycin at 37 °C in a humidified incubator with 5 % CO2. Cells were seeded 48 h prior to treatments at a density of 1 x 10⁶ cells/100-mm dish. For glucose deprivation treatments, cells were washed twice with glucose-free DMEM (Mediatech) supplemented with 10 % (v/v) dialyzed FBS (Invitrogen) and penicillin/streptomycin and then incubated in the same media for the indicated times.

For inhibitor treatments, the protocol was modified as follows. Thirty minutes prior to the start of glucose deprivation, DMSO (Sigma), 20 μM compound C (EMD Biosciences), 5 μg/mL actinomycin D (Sigma), or 10 μM SB203580 (Sigma) were added to the cells. After 30 min, the cells were washed twice with glucose-free media containing the respective inhibitor and then incubated in the same media for the indicated times.

For metformin treatments, 5 mM metformin (Sigma) dissolved in PBS was added to the plates and incubated for the indicated times.

Plasmids and Transfections – Mammalian expression vectors encoding HA-tagged p38alpha, MKK3, MKK3 AA, or MKK3 EE were a kind gift of Dr. J. Silvio Gutkind (National Institute of Dental and Craniofacial Research, NIH, Bethesda, Maryland) (39). The mammalian expression vector encoding an untagged form of OGT, pShuttle-OGT, was described previously (9). The prokaryotic expression vector encoding nOGT was a kind gift of Dr. Suzanne Walker (Harvard Medical School, Boston, Massachusetts) (40).

A mammalian expression vector expressing GST-tagged full-length rat OGT (pEF-GST-OGT) was constructed using standard PCR methods using pShuttle-OGT (9) as template. GST-tagged N-terminal OGT truncations were constructed by PCR using the following 5’ primers (939: AGA TCT GAG ACT CTT GCC TCT CGA GTT GCA GCT; 959: AGA TCT ATT GCT AAA AGC...
AGA CAG GAA TAT GAA; 979: AGA TCT TAC CTG AAG AAA ATT CGT GGC AAA GTA; 999: AGA TCT ACC AAA CAA TAC ACA ATG GAA TTA GAG; 1019: AGA TCT GCT GGC AAC AAA CCC GAC CAC ATG ATT) and the 3´ primer (GAA TTC TCA GGC TGT GGC AAC GTG; 3´: GC GGC CGC TCA TTC TAG ATC GGT CCC CAG TTT), digested with BglII/EcoRI, and subcloned into the BamHI/EcoRI sites of pEF-GST. The GST-tagged C-terminal OGT truncation, GST-OGT(1-978), was created by PCR using the following primers (5´: GGA TCC ATG GCG TCT TCC GTG GGC AAC GTG; 3´: GC GGC CGC TCA TTC TAG ATC GGT CCC CAG TTT), digested with BamHI/NotI, and subcloned into the BamHI/NotI sites of pEF-GST.

Neuro-2a cells were transfected using Lipofectamine 2000 (Invitrogen) according to manufacturer’s instructions. Adenovirus-mediated overexpression – Neuro-2a cells were infected with adenovirus encoding GFP (Baylor College of Medicine Vector Development Laboratory) or O-GlcNAcase (41) at a multiplicity of infection of 500 for 40 h prior to glucose deprivation.

Protein Analysis – Cells were washed with ice-cold PBS, collected using cell scrapers, and the resulting pellet was flash frozen in dry ice and stored at -80 °C until lysis. For most experiments, cell pellets were lysed with 0.5 % (v/v) Nonidet P-40 (NP-40; Sigma) in 20 mM Tris-HCl, pH 7.5, 140 mM NaCl, 1 mM EDTA, 1 mM PMSF, and 1 µM PUGNAc with protease and phosphatase inhibitors. Cell lysates were then centrifuged to remove debris. For lysing cells to immunoprecipitate NF-H, cell pellets were lysed with 1 % (w/v) SDS in 20 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM PMSF, and 1 µM PUGNAc with protease and phosphatase inhibitors. The lysate was passed 10 times through a 22-gauge needle and 10 volumes of 0.5 % NP-40 lysis buffer (described above) was added to the lysate, homogenized by sonication using a probe sonicator, and centrifuged to remove debris. Protein concentrations were determined by Bradford assay.

For immunoblot analysis, 20 µg of lysate was added to Laemmli buffer, boiled, and separated on Criterion pre-cast SDS-PAGE gels (Bio-Rad). The gels were subsequently electroblotted to nitrocellulose (Bio-Rad). The membranes were blocked in Tris-buffered saline with 0.1 % (v/v) Tween-20 with either 3 % (w/v) bovine serum albumin or 5 % (w/v) non-fat dry milk. The blocked membranes were then incubated overnight at 4 °C with the appropriate primary antibody against O-GlcNac (CTD110.6), OGT (DM-17; Sigma), O-GlcNAcase (a kind gift of Dr. Stewart Whiteheart, University of Kentucky, Lexington, KY) (41), actin (Sigma), pAMPK (Thr172, 40H9; Cell Signaling), AMPK (Cell Signaling), pp38 (Thr180/Tyr182, Cell Signaling), p38 (Santa Cruz), HA (HA.11; Covance), GST (Covance), NF-H (RMD0 20; Cell Signaling), or tubulin (Sigma). The blots were then washed, incubated with the appropriate secondary antibody, developed using ECL (GE Healthcare), and exposed to Hyperfilm ECL (GE Healthcare). For densitometric lane profiles, the plot profile function in NIH Image v1.63 was used and normalized against actin loading controls.

For co-immunoprecipitation experiments, 1 mg of pre-cleared cell lysate was incubated with 1 µg of antibody against HA (12CA5), pp38, NF-H, or normal mouse IgG overnight at 4 °C. GammaBind G sepharose (GE Healthcare) was added and mixed for an additional 2 h at 4 °C. The immunoprecipitates were then washed, eluted in Laemml buffer, and subjected to immunoblot analysis as described above.

mRNA Analysis – RNA was isolated from cells using Trizol (Invitrogen) according to manufacturer’s instructions. The resulting RNAs were used to prepare oligo-dT-primed cDNA using SuperScript II (Invitrogen) according to manufacturer’s instructions. OGT mRNA and 18S RNA was assayed by qRT-PCR using the following primer pairs (OGT: TC TCG AGT TGC AGC TTC TCA, CA TGT GGT CAG GTT TGT; 18S: AG GAA TTG ACG GAA GGG CAC, GG ACA TCT AAG GGC ATC ACA) with Platinum SYBR Green qPCR SuperMix (Invitrogen) on a MX3000P qPCR machine (Stratagene). The ∆∆Ct method was used to quantitate the relative fold changes in OGT mRNA levels compared to 0 h controls, normalized to 18S RNA.

OGT and O-GlcNAcase Assays – OGT and O-GlcNAcase activity assays were performed as described previously (9) with minor modifications. Neuro-2a lysates were immunoprecipitated using normal rabbit IgG or the OGT-specific antibody
(AL-28) and assayed for [3H]-GlcNAc incorporation from UDP-[3H]-GlcNAc into a substrate peptide derived from CKII (50 mM) for 1 h at room temperature. The reactions were collected onto C18 MacroSpin columns (The Nest Group), washed, eluted with methanol, and counted by scintillation counting. The resulting activity was normalized against the amount of OGT recovered in the immunoprecipitates.

OGT activity was also assayed from whole cell lysates with or without 250 mM CKII peptide using UDP-[3H]-GlcNAc for 1 h at room temperature. Reactions were stopped with 50 mM formic acid, collected onto C18 MacroSpin columns, washed, eluted with methanol, and counted by scintillation counting. “Lysate alone” samples represent incorporation into proteins found in the lysate. “With CKII peptide” samples represent incorporation into proteins found in lysate and CKII peptide. The resulting OGT activity was normalized to either the amount of lysate assayed (Fig. 6C) or the amount of OGT in the lysate (Fig. 6D).

O-GlcNAcase activity was assayed from whole cell lysates using 4 mM pNP-GlcNAc as substrate for 1.5 h at 30 °C. Hydrolyzed pNP was measured and quantitated by absorbance at 405 nm. The resulting O-GlcNAcase activity was normalized to the amount of lysate assayed.

In vitro Kinase Assays – Active recombinant GST-tagged p38alpha (Upstate) was assayed for kinase activity towards recombinant tau and recombinant nCOTG according to manufacturer’s instructions with [gamma 32P]-ATP. Recombinant tau was expressed and purified as described previously (42). nCOTG was expressed and purified as described previously (40). Kinase reactions were stopped with Laemmli buffer, separated by SDS-PAGE, stained with Coomassie G250, dried, and exposed to Hyperfilm ECL.

Metabolite Assays – UDP-GlcNAc and UDP-GalNAc concentrations were determined by capillary zone electrophoresis as described previously (43). ATP concentrations in the same samples were determined using the Kinase-Glo ATP-dependent luciferase assay (Promega).

NF-H Solubility Assays – NF-H solubility was determined as described previously with minor modifications (44). Briefly, cell pellets were initially lysed with 0.5 % NP-40 lysis buffer as detailed above. The lysate supernatant was collected as the NP-40 soluble fraction. The insoluble pellet was washed three times with lysis buffer and then resuspended in 20 mM Tris-HCl, pH 7.5, 8 M urea, 0.1% β-mercaptoethanol, 1 mM PMSF, and 1 μM PUGNAc with protease and phosphatase inhibitors. The suspension was homogenized by sonication, and the resulting supernatant was collected as the insoluble fraction.

Statistical Measurements – All experiments were performed on at least three separate occasions (n ≥ 3). In all charts, error bars represent standard error of the mean (SEM). P-values were calculated using the paired two-tailed Student’s t-test.

RESULTS

Glucose deprivation induces protein O-GlcNAcylation and OGT expression in an AMPK-dependent manner – In order to clarify the role of nutrient sensing in the regulation of O-GlcNAc, we investigated Neuro-2a neuroblastoma cells in the context of glucose deprivation. As expected, there was a slight decrease in protein O-GlcNAcylation at the early (1 – 3 h) timepoints because of decreased flux through the hexosamine biosynthetic pathway. Interestingly, protein O-GlcNAcylation increased significantly and dramatically in the later (6 – 12 h) timepoints in response to glucose deprivation (Fig. 1A). Competition of these protein O-GlcNAcylation immunoblots using GlcNAc shows that the vast majority of these immunoreactive bands are indeed specific for O-GlcNAcylation (Supp. Fig. 1).

We also observed a slight increase in OGT protein and mRNA levels (Fig. 1A and B). These observations are consistent with our previous work showing that many forms of cellular stress induce O-GlcNAcylation, and this response is required for cell survival (9). Also consistent with our previous work, we demonstrate that this increase in protein O-GlcNAcylation is independent of protein degradation (Supp. Fig. 2) and represents an actual increase in OGT activity in vivo. These data are in agreement with a recent report showing that glucose deprivation stimulates O-GlcNAcylation in HepG2 human hepatoma cells (38).

Because the AMPK signaling pathway is known to be activated under glucose deprivation conditions (4,33), we next investigated the
possibility that AMPK could be regulating this increase in protein O-GlcNAcylation.  Pre-treatment of cells with the specific AMPK inhibitor compound C (45) mostly prevented the glucose deprivation-induced increase in protein O-GlcNAcylation (Fig. 2A).  Compound C also prevented the mild increase in OGT protein and mRNA expression induced by glucose deprivation (Fig. 2A and B), suggesting that AMPK regulates OGT expression during glucose deprivation.

To determine if AMPK activation was sufficient for the increase in protein O-GlcNAcylation as seen in glucose deprivation, we treated cells with metformin, a known activator of AMPK signaling (45).  Indeed, metformin treatment increased OGT mRNA and protein expression (Fig. 2C and D).  Treatment of cells with metformin did result in a slight increase in protein O-GlcNAcylation, however the magnitude of the increase was much lower when compared to glucose deprivation (Fig. 2C), suggesting that other stress signaling pathways are required for the maximal induction of protein O-GlcNAcylation as seen with glucose deprivation.

p38 inhibition partially prevents glucose deprivation-induced protein O-GlcNAcylation – The p38 MAPK pathway is activated by many different types of cellular stress (46) and OGT was found to be a putative interactor for p38 in a high-throughput yeast 2-hybrid screen (37), making p38 an attractive potential regulator of protein O-GlcNAcylation. Pre-treatment of cells with the specific p38 inhibitor SB203580 (47) partially prevented the increase in protein O-GlcNAcylation induced by glucose deprivation (Fig. 3A, black arrowheads), without preventing the increase in OGT protein and mRNA expression (Fig. 3A and B).

p38 interacts with the C-terminus of OGT – To verify that p38 and OGT physically interact, we performed co-immunoprecipitation assays using HA-tagged p38alpha with endogenously expressed OGT.  Indeed, OGT was found to co-immunoprecipitate with p38 (Fig. 4A).

Upon scrutiny of the yeast 2-hybrid data, we discovered that the OGT clone found to interact with p38 contained residues 939 to the stop codon (37).  Based on these data, we created N-terminal truncations of OGT to confirm this interaction and further identify the p38-binding site on OGT (Fig. 4B).  Residues 939 – 1036 of OGT were in fact sufficient for binding p38 in this assay (Fig. 4C).  When OGT was truncated to residues 979 – 1036, its binding to p38 was maximal (Fig. 4C), suggesting that residues 939 – 978 may actually be inhibitory to p38 binding.  Further truncation down to residues 999 – 1036 completely abolished binding to p38 (Fig. 4C), suggesting that residues between 979 and 998 are necessary for binding p38.  In fact, residues 979-1036 seem to bind p38 better than full-length OGT (Fig. 4D), in agreement with the hypothesis that other regions of OGT may be inhibitory to p38 binding.

To confirm that the C-terminus of OGT was necessary for binding p38, we created a C-terminal truncation of OGT containing residues 1 – 978.  As expected, OGT (1-978) was not able to interact with p38 (Fig. 4D).  Altogether, these experiments demonstrate that residues 979 – 1036 are necessary and sufficient for binding p38.

OGT interacts with activated p38 during glucose deprivation – In order to understand how p38 could be regulating OGT during glucose deprivation, we sought to determine if its interaction with OGT was altered by glucose deprivation.  Interestingly, OGT’s interaction with p38 increased during glucose deprivation and corresponded with maximal p38 activation at the 9 h timepoint (Fig. 5A).

We next determined if p38 activation was necessary for binding to OGT.  Towards this end, we transfected Neuro-2a cells with plasmids expressing different forms of MKK3, the upstream kinase of p38.  When cells were transfected with the wild type (MKK3) or constitutive active form of MKK3 (EE), OGT was found to interact with pp38 (Fig. 5B).  However, when cells were transfected with the dominant negative form of MKK3 (AA), OGT did not interact with p38 (Fig. 5B), suggesting that activation of p38 is necessary for its interaction with OGT.  Interestingly, the amount of OGT bound to p38 was not increased in the cells expressing MKK3 EE when compared to wild type MKK3 transfected cells, implying that the amount of OGT was a limiting factor.  Next, we overexpressed OGT along with MKK3 EE and found an increase in the amount of OGT bound to p38 (Fig. 5B), confirming that the induction of OGT protein expression is necessary for its increased interaction with p38.

Since activated p38 interacts with OGT, it stood to reason that it might be able to
phosphorylate OGT. In order to examine this possibility, we performed an in vitro kinase assay using recombinant activated p38, and recombinant tau and OGT as substrates. As reported previously, p38 was able to phosphorylate tau protein (Fig. 5C, (48)) as well as ATF2 (data not shown, (49)). However, p38 was not able to phosphorylate recombinant OGT, suggesting that OGT is not a direct substrate of p38 (Fig. 5C). In addition, we sought to determine if OGT would block the phosphorylation of tau by p38 in vitro. However, co-incubation of tau with OGT seemed to have little negative effect on its phosphorylation by p38 and even appeared to slightly increase its phosphorylation (Fig. 5C).

OGT specific catalytic activity and [UDP-GlcNAc] are not increased during glucose deprivation – In order to determine if p38’s interaction with OGT could have an effect on its activity, we next examined OGT’s specific activity by immunoprecipitating OGT and assaying its activity towards the CKII peptide substrate during glucose deprivation. Surprisingly, OGT’s specific catalytic activity was not increased (when corrected for the amount of OGT immunoprecipitated) during glucose deprivation despite the large increase in protein O-GlcNAcylation (Fig. 6A). O-GlcNAcase activity in these same lysates was also not decreased during glucose deprivation (Fig. 6A). In fact, there was a small but significant increase in O-GlcNAcase activity at the 1 h timepoint.

To be sure that UDP-GlcNAc concentrations were not increasing and thus driving the increased protein O-GlcNAcylation, we measured intracellular UDP-GlcNAc, UDP-GalNAc, and ATP concentrations during glucose deprivation. As expected, the concentrations of these metabolites decreased during glucose deprivation by more than two-fold (Fig. 6B).

Next, we set out to confirm that the total OGT activity in the lysate was actually increased by glucose deprivation. We were able to assay OGT activity in whole cell lysate with or without the addition of the CKII peptide substrate and found that total OGT activity did indeed increase during glucose deprivation (Fig. 6C). However, these increases disappear when normalized to the amount of OGT in the lysate (Fig. 6D), confirming our earlier experiments showing that OGT’s specific catalytic activity is not increased during glucose deprivation.

p38 recruits OGT to specific targets including neurofilament H during glucose deprivation – Since OGT’s specific catalytic activity was not increased while OGT’s interaction with p38 was increased during glucose deprivation, we put forth the hypothesis that p38 may be interacting with OGT and targeting it to specific substrates, thus increasing protein O-GlcNAcylation during glucose deprivation. In an attempt to test this hypothesis, we performed a large-scale co-immunoprecipitation to identify proteins that interact with OGT during glucose deprivation (data not shown). One potential target identified by this screen was neurofilament H (NF-H), a known substrate of both OGT and p38 (50,51).

In order to confirm that NF-H interacted with OGT during glucose deprivation, we performed co-immunoprecipitation assays using endogenously expressed NF-H and OGT. As expected, NF-H interacted with OGT during glucose deprivation (Fig. 7A). More importantly, O-GlcNAcylation of a faster migrating form (110 kDa apparent MW) of NF-H increased during glucose deprivation (Fig. 7A).

To demonstrate that NF-H O-GlcNAcylation during glucose deprivation required p38, we pre-treated cells with SB203580. Indeed, inhibition of p38 abolished the glucose deprivation-induced O-GlcNAcylation of NF-H (Fig. 7B), suggesting that p38 activity is required for OGT’s ability to O-GlcNAcylate NF-H. Surprisingly, inhibition of p38 did not seem to affect OGT’s interaction with NF-H during glucose deprivation (Fig. 7B), suggesting that OGT’s interaction with NF-H may not necessarily be p38-dependent, whereas its activity towards NF-H requires p38 activation.

Neurofilament H solubility is increased by O-GlcNAcylation during glucose deprivation – In order to examine what effect NF-H O-GlcNAcylation may be having on its function, we determined its solubility during glucose deprivation. NF-H solubility increased dramatically during glucose deprivation (Fig. 7C), indicating a shift in the pool of NF-H from the insoluble filamentous form to a more soluble form (44).

Next, we determined if NF-H O-GlcNAcylation was required for this increase in solubility during glucose deprivation by using
adenoviral-mediated overexpression of O-GlcNAcase. Overexpression of O-GlcNAcase completely prevented the increase in NF-H solubility during glucose deprivation (Fig. 7D), suggesting that O-GlcNAcylation of NF-H is necessary for increasing its solubility.

To further confirm that O-GlcNAcylation affects NF-H solubility, we took advantage of the observation that GST-OGT979-1036 appears to bind p38 better than full length OGT. Because this short fragment lacks the catalytic portion of OGT, overexpression of this protein would not be expected to increase O-GlcNAcylation and should effectively compete with endogenous OGT for binding to p38. In order to demonstrate that GST-OGT979-1036 competes the OGT-p38 interaction, we performed co-immunoprecipitation assays and found that overexpression of this fragment decreases the amount of endogenous OGT bound to p38 (Fig. 8A).

Next, we determined if GST-OGT979-1036 could prevent the increase in NF-H solubility seen during glucose deprivation. As expected, overexpression of GST-OGT979-1036 prevented the glucose deprivation-induced increase in NF-H solubility (Fig. 8B), suggesting that OGT’s interaction with p38 is necessary for NF-H solubility.

DISCUSSION

Physiologically, glucose deprivation can occur in a number of instances, including during ischemic events and as a result of aging in the brain (1,52). During cerebral ischemia, the brain is deprived of oxygen as well as glucose (1). It has been observed that ischemia directly results in selective injury and loss of axons in the brain (6,7). However, the precise mechanisms underlying ischemic-induced axonal damage remain unclear.

Glucose metabolism in the brain has been shown to decline with age (52,53). While the brain is able to use ketone bodies as a minor source of fuel, glucose remains the primary source of energy for the brain (54). While the direct effects of limiting glucose usage on brain function are not clearly understood, studies showing that glucose deprivation leads to axonal loss imply that it has negative consequences for brain function (6,7). In fact, it has been proposed that the age-related decline in glucose metabolism and the resulting reduced O-GlcNAcylation of neuronal proteins could be a key mediator in the development of late-onset Alzheimer’s disease (55-59). It is worthy to note that the incidence of dementia and Alzheimer’s disease is significantly increased in patients following cerebral ischemia (60-62), suggestive of a direct association between defective glucose metabolism and brain function.

Here, we report a potential mechanism by which glucose deprivation may influence axonal structural stability (Fig. 9). We present evidence that glucose metabolism activates AMPK, which mediates an increase in OGT mRNA and protein expression. During glucose deprivation, p38 is also activated, and this activation is required for its interaction with OGT. This p38-OGT interaction seems to alter OGT’s function in a way such that specific proteins, including NF-H, are now better substrates for OGT, possibly by directly recruiting OGT to target sequences or sites. One effect of this p38-mediated activation of OGT is the O-GlcNAcylation of NF-H, resulting in its depolymerization from neurofilaments or other intermediate filament structures. NF-H is a major structural component of mature axons, the loss of which in neurofilaments has negative consequences on axonal structure and caliber (63).

NF-H is a type IV intermediate filament protein with a head, rod, and tail domain. The central coiled-coil alpha-helical rod domain allows NF-H to form heterotetramers with NF-L or NF-M, but this domain is not known to be phosphorylated or O-GlcNAcylated (50,64). The C-terminal tail domain of NF-H, which protrudes and forms a side-arm from the neurofilaments, contains greater than 30 Lys-Ser-Pro (KSP) repeat phosphorylation sites (64). Recently, Ackerley and colleagues demonstrated that p38alpha can phosphorylate several of these KSP repeats on NF-H and can associate with phosphorylated neurofilament aggregations, as seen in amyotrophic lateral sclerosis (ALS) (51). Our lab has previously shown that many of these KSP repeats on NF-H can also be O-GlcNAcylated, however its functional significance remains unclear (50). Interestingly, Ludemann and colleagues have shown that O-GlcNAcylation of the KSP repeats in NF-M, which has a much shorter tail domain, seems decreased in ALS while its phosphorylation is increased, suggesting a
direct reciprocal relationship between O-GlcNAcylation and phosphorylation of the tail domain of NFs (65). Nonetheless, it is not known how NF-H tail domain phosphorylation/O-GlcNAcylation might affect its solubility. Instead, NF-H tail phosphorylation has been shown to affect axonal transport of neurofilaments (66,67). In general, phosphorylation of the head domain of intermediate filament proteins is thought to control its polymerization into filaments (67). Only one phosphorylation site at Ser61 in the head domain of NF-H has been identified (68). Whether phosphorylation of NF-H at this site affects its assembly has not been investigated at this time. In contrast, there are three known sites of O-GlcNAcylation in the head domain of NF-H at Thr53, Ser54, and Ser56 (50). But, the precise function of O-GlcNAcylation on these residues is also not known. Further studies regarding the phosphorylation and O-GlcNAcylation of the head domain of NF-H will help to elucidate their roles in regulating the assembly and solubility of neurofilaments. Also, the significance of the increase in solubility of NF-H in terms of cell survival is not completely understood. Although loss of neurofilaments has been shown to be associated with axonal damage (69), whether or not this is actually beneficial to the overall survival of the cell remains unclear.

The fact that p38 is a positive regulator of NF-H O-GlcNAcylation during glucose deprivation suggests that this is part of a stress response pathway. Surprisingly, instead of interacting with OGT through its N-terminal TPR motifs, p38 interacts with OGT’s C-terminus, a region proximal to its catalytic domain. It is possible that binding of p38 to OGT may induce a conformational change in OGT, altering its ability to recognize certain proteins or sequences. Clearly, p38’s role in mediating O-GlcNAcylation during glucose deprivation and other forms of cellular stress warrants further investigation. In fact, recent studies suggest that the p38 pathway itself may be regulated by the hexosamine biosynthetic pathway and O-GlcNAcylation (70,71).

Furthermore, while p38 does not directly phosphorylate OGT in vitro, our data cannot rule out the possibility that OGT may be phosphorylated by another kinase(s) under these conditions. However, our observation that OGT’s specific catalytic activity is not changed during glucose deprivation suggests that phosphorylation of OGT is unlikely to directly affect its catalytic activity (Fig. 6A, C, D). Instead, phosphorylation of OGT may affect its ability to recognize its substrates or its interaction with other targeting proteins. It should be noted that p38 inhibition only partially prevented glucose deprivation-induced protein O-GlcNAcylation (Fig. 3A), implying that there are many other unknown OGT targeting proteins. The identification of other proteins that are O-GlcNAcylated during glucose deprivation may be a promising avenue for revealing some of these OGT regulating proteins. Furthermore, this mode of OGT’s regulation through recruitment may also extend to other forms of cellular stimulation.

Regardless of how OGT is being targeted to its substrates during glucose deprivation, its increased expression by AMPK seems to be a critical prerequisite, since inhibition of AMPK almost completely blocks the glucose deprivation-induced O-GlcNAcylation (Fig. 2A). Our data indicate that AMPK is a positive regulator of OGT mRNA expression. The transcription factors that are responsible for regulating transcription of OGT are unknown. In actuality, our data implies that AMPK might be regulating OGT mRNA stability, since inhibition of transcription merely prevented the glucose deprivation-induced increase in OGT mRNA while inhibition of AMPK caused a decrease in OGT mRNA during glucose deprivation (Fig. 2B). In accordance with this hypothesis, Yun and coworkers have shown that, during glucose deprivation of DU145 prostate carcinoma cells, VEGF mRNA stability is increased in an AMPK-dependent manner (72). However, our observations cannot rule out the possibility that OGT expression may also be regulated transcriptionally, as well as translationally.

Recently, Taylor et al. showed that glucose deprivation induced protein O-GlcNAcylation and OGT expression in HepG2 hepatoma cells (38). While our data showing that glucose deprivation induces protein O-GlcNAcylation are largely in agreement with that report, here we are able to outline several means by which OGT and protein O-GlcNAcylation are regulated during glucose deprivation by AMP-activated protein kinase and p38 MAP kinase signaling pathways, resulting in
NF-H O-GlcNAcylation and alteration of its solubility. These findings represent a possible mechanism by which defective glucose metabolism may influence axonal structural stability. A greater understanding of how protein O-GlcNAcylation is regulated during glucose deprivation may lead to better mechanistic insights into cerebral ischemia, aging, neurodegeneration, and cancer.

REFERENCES

47. Cuenda, A., Rouse, J., Doza, Y. N., Meier, R., Cohen, P., Gallagher, T. F., Young, P. R.,
    *FEBS Lett* **409**(1), 57-62
49. Derijard, B., Raingeaud, J., Barrett, T., Wu, I. H., Han, J., Ulevitch, R. J., and Davis, R. J.
    20845-20852
51. Ackerley, S., Grierson, A. J., Banner, S., Perkinton, M. S., Brownlees, J., Byers, H. L.,
    Ward, M., Thornhill, P., Hussain, K., Waby, J. S., Anderton, B. H., Cooper, J. D.,
    354-364
55. Fukuyama, H., Ogawa, M., Yamauchi, H., Yamaguchi, S., Kimura, J., Yonekura, Y., and
    *J Biol Chem* **271**(46), 28741-28744
    Sci U S A* **101**(29), 10804-10809
62. Vermeer, S. E., Prins, N. D., den Heijer, T., Hofman, A., Koudstaal, P. J., and Breteler,
63. Elder, G. A., Friedrich, V. L., Jr., Kang, C., Bosco, P., Gourov, A., Tu, P. H., Zhang, B.,
    Sci* **31**(7), 383-394
    Biol Chem* **280**(36), 31648-31658
    1818-1829
68. Trinidad, J. C., Specht, C. G., Thalhammer, A., Schoepfer, R., and Burlingame, A. L.
    Physiol* **27**(7), 548-552

FOOTNOTES

* This work was supported by a NSF Graduate Research Fellowship to W.D.C. and by NIH R01 HD13563 and CA42486 to G.W.H. Under a licensing agreement between The Johns Hopkins University, Covance Research Products, Sigma-Aldrich, and Santa Cruz Biotechnology, G.W.H. receives royalties from the sale of the CTD110.6 O-GlcNAc antibody.

The abbreviations used are: O-GlcNAc, O-linked beta-N-acetylglucosamine; O-GlcNAcase, O-linked beta-N-acetylglucosaminidase (EC 3.2.1.52); OGT, O-linked beta-N-acetylglucosaminyltransferase (EC 2.4.1.94); AMPK, AMP-activated protein kinase; tuberin, TSC2; mTOR, mammalian target of rapamycin; DMEM, Dulbecco’s modified Eagle medium; FBS, fetal bovine serum; DMSO, dimethyl sulfoxide; PBS, phosphate-buffered saline; NF-H, neurofilament H; ALS, amyotrophic lateral sclerosis.

ACKNOWLEDGMENTS

We greatly appreciate the gift of mammalian expression plasmids encoding p38 and MKK3 from Dr. J. Silvio Gutkind (National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland) and the prokaryotic expression plasmid encoding ncOGT from Dr. Suzanne Walker (Harvard Medical School, Boston, Massachusetts). We also appreciate the generous gift of O-GlcNAcase antibodies from Dr. Stewart Whiteheart (University of Kentucky, Lexington, Kentucky). We thank Kaoru Sakabe for creating the GST-tagged full-length OGT mammalian expression plasmid. We also thank Tonia Vassilowitch, Michael Housley, Dr. Wagner Dias, Dr. Chad Slawson, and other members of the laboratory for technical assistance and critical reading of this manuscript.

FIGURE LEGENDS

Fig. 1. Glucose deprivation induces protein O-GlcNAcylation and OGT expression. A. Lysates from Neuro-2a cells glucose deprived for the indicated times were immunoblotted for O-GlcNAc, OGT, and actin. B. mRNA prepared from Neuro-2a cells glucose deprived for the indicated times were subjected to qRT-PCR using primers specific for OGT and 18S RNA. * P<0.05 compared to 0 h control.

Fig. 2. AMPK is necessary but not sufficient for glucose deprivation-induced protein O-GlcNAcylation. A. Lysates from Neuro-2a cells glucose deprived for the indicated times (following 30 min pre-treatment with DMSO or 20 µM compound C) were immunoblotted for O-GlcNAc, OGT, pAMPK, AMPK, and actin. B. mRNA prepared from Neuro-2a cells glucose deprived for the indicated times (following 30 min pre-treatment with DMSO, 20 µM compound C, or 5 µg/mL actinomycin D) were subjected to qRT-PCR using primers specific for OGT and 18S RNA. C. Lysates from Neuro-2a cells treated for the indicated times with 5 mM metformin or glucose deprivation were immunoblotted for O-GlcNAc, OGT, pAMPK, AMPK, and actin. D. mRNA prepared from Neuro-2a cells treated with 5 mM metformin for the indicated times were subjected to qRT-PCR using primers specific for OGT and 18S RNA. * P<0.05 compared to 0 h control.

Fig. 3. Inhibition of p38 partially prevents glucose deprivation-induced protein O-GlcNAcylation. A. Lysates from Neuro-2a cells glucose deprived for the indicated times (following 30 min pre-treatment with DMSO or 10 µM SB203580) were immunoblotted for O-GlcNAc, OGT, pp38, p38, and actin.
Densitometric lane profiles for the 9 h timepoints (subtracted by the 0 h timepoints and normalized to actin loading) are displayed for the O-GlcNAc immunoblot. Black arrowheads mark bands decreased by SB203580 and the gray arrowhead marks bands increased by SB203580. 

**Fig. 4.** p38 interacts with the C-terminus of OGT.  
A. Lysates from Neuro-2a cells transfected with HA or HA-p38alpha were immunoprecipitated for HA and immunoblotted for OGT and HA.  
B. Diagram of GST-tagged OGT N-terminal truncations created and tested for the ability to interact with p38.  
C and D. Lysates from Neuro-2a cells transfected with the indicated constructs were immunoprecipitated for HA and immunoblotted for GST and HA.

**Fig. 5.** OGT interacts with the activated form of p38.  
A. Lysates from Neuro-2a cells transfected with HA or HA-p38alpha and glucose deprived for the indicated times were immunoprecipitated for HA and immunoblotted for OGT, pp38, and HA.  
B. Lysates from Neuro-2a cells transfected with MKK3, MKK3 AA, MKK3 EE, or MKK3 EE with OGT were immunoprecipitated for pp38 or normal mouse IgG and immunoblotted for OGT and pp38.  
C. 50 ng of activated recombinant GST-p38 was assayed for *in vitro* kinase activity towards recombinant tau (2 µg), recombinant OGT (8 µg), or recombinant tau in the presence of OGT.

**Fig. 6.** Glucose deprivation-induced protein O-GlcNAcylation cannot be explained by OGT specific catalytic activity or UDP-GlcNAc concentrations.  
A. OGT immunoprecipitates from Neuro-2a cells glucose deprived for the indicated times were assayed for OGT activity (closed circles, solid lines) and normalized to the amount of OGT immunoprecipitated (inset). Lysates from Neuro-2a cells glucose deprived for the indicated times were assayed for O-GlcNAcase activity (open circles, dashed lines) as described in “Experimental Procedures.”  
B. Lysates from Neuro-2a cells glucose deprived for the indicated times were assayed for UDP-GlcNAc, UDP-GalNAc, and ATP concentrations as described in “Experimental Procedures.”  
C. Lysates from Neuro-2a cells glucose deprived for the indicated times were assayed for OGT activity.  
D. Experiment in C normalized to the amount of OGT in the lysates. *P<0.05 compared to 0 h control.

**Fig. 7.** During glucose deprivation, NF-H is O-GlcNAcylated in a p38-dependent manner and its solubility is increased.  
A. Lysates from Neuro-2a cells glucose deprived for the indicated times were immunoprecipitated for NF-H or normal mouse IgG and immunoblotted for NF-H, O-GlcNAc, and OGT. Asterisk marks O-GlcNAcylated NF-H species. NS, non-specific bands appearing in normal IgG immunoprecipitates.  
B. Lysates from Neuro-2a cells glucose deprived for the indicated times (following 30 min pre-treatment with DMSO or 10 µM SB203580) were immunoprecipitated for NF-H or normal mouse IgG and immunoblotted for NF-H, O-GlcNAc, and OGT. Asterisk marks O-GlcNAcylated NF-H species. NS, non-specific bands appearing in normal IgG immunoprecipitates.  
C. NP-40 soluble and insoluble fractions prepared from Neuro-2a cells glucose deprived for the indicated times were immunoblotted for NF-H, tubulin, and actin.  
D. NP-40 soluble and insoluble fractions prepared from Neuro-2a cells infected with GFP or O-GlcNAcase adenovirus and glucose deprived for the indicated times were immunoblotted for NF-H, O-GlcNAc, O-GlcNAcase, GFP, tubulin, and actin.

**Fig. 8.** GST-OGT\textsubscript{979-1036} overexpression disrupts the OGT-p38 interaction and prevents the glucose deprivation-induced NF-H solubility change.  
A. Lysates from Neuro-2a cells transfected with the indicated constructs were immunoprecipitated for HA and immunoblotted for OGT, GST, and HA.  
B. NP-40 soluble and insoluble fractions prepared from Neuro-2a cells transfected with GST or GST-OGT\textsubscript{979-1036} and glucose deprived for the indicated times were immunoblotted for NF-H, GST, tubulin, and actin.
Fig. 9. Model for OGT regulation by AMPK and p38 during glucose deprivation. Glucose deprivation activates AMPK via an increase in the AMP/ATP ratio, resulting in increased OGT expression. Glucose deprivation activates p38 by phosphorylation, which interacts with OGT, recruiting it to specific targets including neurofilament H to increase its solubility.
Figure 1

A

Time of glucose deprivation

0 1 3 6 9 12 h

IB: O-GlcNAc

IB: OGT

IB: actin

B

Fold Change in OGT mRNA / 18S

0 0.5 1 1.5 2

Time of glucose deprivation (h)

0 3 6

1.00 0.91 1.49 1.59
Figure 2

A

Time of glucose deprivation
0 1 3 6 9 h

IB: O-GlcNAc
IB: OGT
IB: pAMPK
IB: AMPK
IB: actin
DMSO 20 μM Compound C

C

Time of treatment
0 1 3 6 9 15 0 9 h

IB: O-GlcNAc
IB: OGT
IB: pAMPK
IB: AMPK
IB: actin
5 mM metformin glucose deprivation

B

Fold change in OGT mRNA / 18S

Time of glucose deprivation (h) 0 3 6

D

Fold change in OGT mRNA / 18S

Time of metformin treatment (h) 0 3 6

1.41 *
Figure 3

A

Time of glucose deprivation

0 1 3 6 9

Relative O-GlcNAc at 9 h (minus 0 h)

IB: O-GlcNAc

IB: OGT

IB: pp38

IB: p38

IB: actin

DMSO 10 μM SB203580

B

Fold change in OGT mRNA / 18S

0 0.5 1 1.5 2 2.5

0 3 6

Time of glucose deprivation (h)

DMSO SB203580

1.72 1.93

1.54 1.56
Figure 5

A

Time of glucose deprivation

IB: OGT
IP: HA
IB: OGT
IP: HA
IP: pp38
IP: HA
IB: HA

HA HA-p38α

B

pp38 IP IgG pp38 IP

MKK3 AA EE EE EE + OGT

IB: OGT
IB: OGT
IB: pp38

input IP

C

p38 + + + +
tau - + - +
OGT - - + +

3P Autorad

OGT GST-p38 tau
Figure 7

A

Time of glucose deprivation
0 9 0 9 0 9 h

IB: NF-H

IB: O-GlcNAc

IB: OGT

Input IgG NF-H IP 1Ps

B

Time of glucose deprivation (h)
0 9 9 0 9 9 0 9 9

DMSO + + + + + +

10 µM SB203580 - - + - + - +

IB: NF-H

IB: O-GlcNAc

IB: OGT

Input IgG NF-H IP 1Ps

C

Time of glucose deprivation
0 1 3 6 9 0 1 3 6 9 h

IB: NF-H

IB: tubulin

IB: actin

NP-40 soluble insoluble

D

Time of glucose deprivation (h)
GFP 0 9 0 9 0 9

O-GlcNAcase 0 9 0 9

IB: NF-H

IB: O-GlcNAc

IB: O-GlcNAcase

IB: GFP

IB: tubulin

IB: actin

sol insol sol insol
Figure 8

A

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th>Time of glucose deprivation (h)</th>
<th>GST</th>
<th>GST-OGT&lt;sub&gt;979-1036&lt;/sub&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- IB: NF-H
- IB: GST
- IB: tubulin
- IB: actin

sol | insol | sol | insol
Figure 9

Glucose deprivation

p38

OGT

AMPK

AMP

ATP

[OGT mRNA]↑
AMP-activated protein kinase and P38 map kinase activate O-GlcNAcylation of neuronal proteins during glucose deprivation

Win D. Cheung and Gerald W. Hart

J. Biol. Chem. published online March 19, 2008

Access the most updated version of this article at doi: 10.1074/jbc.M801222200

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC’s e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2008/03/21/M801222200.DC1

This article cites 0 references, 0 of which can be accessed free at
http://www.jbc.org/content/early/2008/03/19/jbc.M801222200.citation.full.html#ref-list-1